Compare GeneDx Holdings Corp (WGS) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Williams-Sonoma, Inc. — how do they compare? GeneDx Holdings Corp trades at $67.33 (market cap $2.02B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 13.9× GeneDx Holdings Corp's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Williams-Sonoma, Inc. for 59 Days on average.
| WGS | WSM | |
|---|---|---|
Market Cap | $2.02B | $28.15B |
Volume | 734,640 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $167.51 | $251.81 |
52-Week Low | $34.51 | $168.64 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $2.05B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, near its pivot point of $239 with bullish moving average signals. The company demonstrates strong profitability with a 14.73% net income margin and 54.96% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights market share gains and margin expansion through reduced discounting, with a new Pottery Barn collaboration and store openings fueling growth.
The outlook remains positive with a consensus price target of $246.31 offering 3% upside, though risks include housing market sensitivity and high valuation multiples. Earnings growth and disciplined cost control position WSM for continued outperformance, but investors should monitor competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
